Early Life
Herriot Tabuteau was born in Haiti and immigrated to the United States at the age of nine. Growing up in Manhattan, he was surrounded by a stimulating scientific environment, which cultivated his early interest in science and medicine. He credits his strong work ethic to his father, and his historical perspective and appreciation for art and literature to his mother. Tabuteau attended Wesleyan University, where he earned a bachelor's degree in molecular biology and biochemistry. He later pursued a medical degree from Yale University School of Medicine.
Rise to Success
Prior to founding Axsome Therapeutics, Tabuteau worked in healthcare finance. He was a partner at the hedge fund Healthco/S.A.C. Capital, gaining experience in the complexities of the biotech sector. In 2012, Tabuteau founded Axsome Therapeutics with a mission to address brain disorders such as depression, ADHD, and Alzheimer's disease. He self-funded the company, which allowed him to control and shape its innovative approach.
Key Business Strategies
Axsome Therapeutics distinguishes itself by focusing on treatments for brain disorders, a notoriously challenging area. Tabuteau implemented an innovative approach by diversifying its drug portfolio and conducting clinical trials in-house, cutting costs and increasing efficiency. This strategy allowed him to develop drugs faster and more effectively. The company has successfully launched three FDA-approved drugs, including Auvelity for major depressive disorder, and has several more in its pipeline.
Philanthropy
While specific amounts are not readily available, Dr. Tabuteau's success has positioned him to potentially engage in various philanthropic efforts, aligned with his values and commitment to improving lives through advancements in healthcare.
